Raptor Pharmaceutical Corp 4
4 · Raptor Pharmaceutical Corp · Filed Oct 26, 2016
Insider Transaction Report
Form 4
Gould Ashley C.
SVP Gen Counsel-CorpGovernance
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2016-10-25−44,054→ 0 totalExercise: $3.74Exp: 2026-02-09→ Common Stock (44,054 underlying) - Disposition from Tender
Common Stock
2016-10-24$9.00/sh−9,286$83,574→ 36,690 total - Disposition to Issuer
Common Stock
2016-10-25$9.00/sh−36,690$330,210→ 0 total
Footnotes (3)
- [F1]Shares tendered in connection with an offer to purchase all of the issued and outstanding shares of common stock of Raptor Pharmaceutical Corp. ("Raptor"), par value $0.001 per share, for an amount of $9.00 per share in cash, without interest and less any applicable withholding taxes, commenced pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 12, 2016, by and among Raptor, Horizon Pharma plc, a public limited company organized under the laws of Ireland ("Parent") and Misneach Corporation, a Delaware corporation and an indirect wholly owned subsidiary of Parent.
- [F2]Pursuant to the Merger Agreement, on October 25, 2016, each outstanding restricted stock unit was accelerated in full and cancelled in exchange for the right to receive $9.00 per share in cash, without interest and less any required withholding taxes.
- [F3]Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes.